Follicular Lymphoma

Treatment with Brukinsa and Gazyva poses a new option for certain patients with follicular lymphoma, with tolerable side effects, an expert told CURE®.

I've learned that there are many differing perspectives when it comes to treatment for cancer, especially from patients to researchers.

The Food and Drug Administration approved Brukinsa plus Gazyva for patients with relapsed or refractory follicular lymphoma who have undergone two or more prior lines of therapy.

When I told my friends I started feeling better during cancer treatment, they were all so confused.

Having all of these screenings for cancer terrifies me, even though they could be almost certainly nothing.

Whenever I experience a new ache or patch of itchy skin, I immediately think it's a health issue — or a recurrence.

Researchers reported long-lasting responses and no new safety concerns in patients with relapsed/refractory follicular lymphoma during the 2023 ASH Annual Meeting and Exposition.

Please don’t tell me I have the “good” kind of cancer or comment on how much weight I’ve lost.

The Food and Drug Administration will speed up the review of odronextamab for patients with relasped or refractory follicular lymphoma or diffuse large B-cell lymphoma.

One patient was able to access a therapy for follicular lymphoma before it was approved by the FDA, which allowed him to help future patients through his experience.

Patients with relapsed/refractory follicular lymphoma — a group that traditionally has limited treatment options — now have a new bispecific antibody available.

The combination treatment demonstrated survival and safety results similar to those of chemotherapy for patients with advanced, untreated follicular lymphoma.

The FDA approval of Breyanzi, a novel CAR-T cell therapy, provides many patients with lymphoma a new treatment option that can be used earlier in the course of their disease, according to an expert.

The priority review comes following positive clinical trial results, which may lead to a shift in the treatment paradigm for follicular lymphoma, according to an expert.

Kymriah, a CAR-T cell therapy, was approved by the Food and Drug Administration for the treatment of patients with pretreated, relapsed/refractory follicular lymphoma.

Treatment with TRPH-222 led to lasting responses in certain patients with relapsed/refractory B-cell non-Hodgkin lymphomas, warranting a larger investigation into the drug, according to the researchers.

Kymriah may represent a more effective option than currently available treatments for patients with heavily pretreated follicular lymphoma, according to an expert from The University of Texas MD Anderson Cancer Center.

New findings show that 43% of patients with certain blood cancers produced COVID-19 antibodies after receiving a third full dose of the mRNA vaccine.

The Food and Drug Administration will review parsaclisib for the treatment of patients with follicular lymphoma, marginal zone lymphoma and mantle cell lymphoma.

Kymriah was granted a priority review for the treatment of pretreated patients with relapsed or refractory follicular lymphoma.

This accelerated FDA approval is the first CAR T-cell therapy approved for the treatment of patients with indolent follicular lymphoma.

Local access to national cancer studies allows patients to receive promising new treatments in the most convenient setting possible: Their own community.

The Food and Drug Administration has granted an accelerated approval to Ukoniq for the treatment of certain adults with previously treated relapsed or refractory marginal zone lymphoma and relapsed or refractory follicular lymphoma.

A roundup of some of the most read news and updates in follicular lymphoma in 2020 from CURE®.

Aileen Holthaus writes about her first day of chemotherapy for follicular lymphoma, and the challenges it presented.

One recently approved drug and two experimental treatments offer the promise of a wider range of options for patients with follicular lymphoma, according to Dr. Germame Ajebo.

Bob Meyers and his daughter Leslie Watson have always been close. In fact, they live right down the street from one another in their Georgia neighborhood. So, when Watson received the diagnosis of clear cell carcinoma in the summer of 1996, and then follicular lymphoma later that fall, Meyers was there by her side as her devoted caregiver.

In addition to showing clinically meaningful, durable responses, Tazverik (tazemetostat) was generally well-tolerated in heavily pretreated patients with relapsed or refractory follicular lymphoma, according to the results of an open-label, single-arm, multicenter phase 2 study.

A study evaluating the efficacy of Aliqopa (copanlisib) in combination with Rituxan (rituximab) in patients with indolent non-Hodgkin’s lymphoma who have relapsed after at least one prior line of therapy also involving Rituxan has met its primary endpoint, according to Aliqopa’s manufacturer, Bayer.

“Collectively, our mature data provide the most definitive evidence supporting current guidelines, that HDT/ASCT should not be offered to unselected patient(s) (with follicular lymphoma) in the frontline setting,” the authors wrote.